Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan

Overview

Journal Invest Ophthalmol Vis Sci

Specialty Ophthalmology

Date 2024 Jun 12

PMID 38864813

Authors

Hou-Ren Tsai

Yu-Jie Lin

Jih-I Yeh

Shu-Man Lin

Peter Pin-Sung Liu

Yung-Ching Chang

Yuan-Chieh Lee

Ching-Hui Loh

Huei-Kai Huang

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to evaluate the risk of newly diagnosed retinal vein occlusion (RVO) in patients with type 2 diabetes (T2D) using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) compared to dipeptidyl peptidase-4 inhibitors (DPP-4i).

Methods: Claims data from the National Health Insurance Research Database of Taiwan were used in this nationwide retrospective cohort study. A target trial emulation framework was applied. Patients with T2D with no prior diagnosis of RVO who had newly commenced treatment with SGLT-2i or DPP-4i between May 1, 2016, and December 31, 2020, were included. Potential systematic differences in baseline characteristics between the paired groups were controlled using stabilized inverse probability of treatment weighting. The outcome of interest was incident RVO. The hazard ratio (HR) for SGLT-2i compared with that of DPP-4i was estimated using a Cox regression model.

Results: Data from 123,567 and 578,665 patients receiving SGLT-2i and DPP-4i, respectively, were analyzed. The incidence of RVO was lower in patients newly receiving SGLT-2i (0.59 events per 1000 person-years) compared to those receiving DPP-4i (0.77 events per 1000 person-years) over a mean follow-up of 1.61 years. SGLT-2i users had a significantly lower risk of developing RVO compared with DPP-4i users (HR = 0.76, 95% confidence interval [CI] = 0.59-0.98). In the individual outcome analysis, SGLT-2i use was significantly associated with a lower risk of branch RVO (HR = 0.71, 95% CI = 0.52-0.96), but not central RVO (HR = 0.84, 95% CI = 0.57-1.24).

Conclusions: The risk of developing RVO was lower in patients with T2D receiving SGLT-2i compared with that in those receiving DPP-4i.

References

Hsieh C, Su C, Shao S, Sung S, Lin S, Kao Yang Y . Taiwan's National Health Insurance Research Database: past and future. Clin Epidemiol. 2019; 11:349-358. PMC: 6509937. DOI: 10.2147/CLEP.S196293. View

Austin P . Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009; 28(25):3083-107. PMC: 3472075. DOI: 10.1002/sim.3697. View

Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A . Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017; 16(1):8. PMC: 5237208. DOI: 10.1186/s12933-016-0491-5. View

Cugati S, Wang J, Rochtchina E, Mitchell P . Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol. 2006; 124(5):726-32. DOI: 10.1001/archopht.124.5.726. View

Bhattacharjee H, Barman M, Misra D, Multani P, Dhar S, Behera U . Spectrum of Eye Disease in Diabetes (SPEED) in India: A prospective facility-based study. Report # 3. Retinal vascular occlusion in patients with type 2 diabetes mellitus. Indian J Ophthalmol. 2020; 68(Suppl 1):S27-S31. PMC: 7001162. DOI: 10.4103/ijo.IJO_1934_19. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Francis P, Stanford M, Graham E . Dehydration is a risk factor for central retinal vein occlusion in young patients. Acta Ophthalmol Scand. 2003; 81(4):415-6. DOI: 10.1034/j.1600-0420.2003.00095.x. View

Wu J, Foote C, Blomster J, Toyama T, Perkovic V, Sundstrom J . Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016; 4(5):411-9. DOI: 10.1016/S2213-8587(16)00052-8. View

Shao S, Chang K, Lin S, Chien R, Hung M, Chan Y . Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients. Cardiovasc Diabetol. 2020; 19(1):17. PMC: 7014757. DOI: 10.1186/s12933-020-0990-2. View

10.

Kutcher S, Brophy J, Banack H, Kaufman J, Samuel M . Emulating a Randomised Controlled Trial With Observational Data: An Introduction to the Target Trial Framework. Can J Cardiol. 2021; 37(9):1365-1377. DOI: 10.1016/j.cjca.2021.05.012. View

11.

Hofler M . The effect of misclassification on the estimation of association: a review. Int J Methods Psychiatr Res. 2005; 14(2):92-101. PMC: 6878572. DOI: 10.1002/mpr.20. View

12.

Lee M, Kim B, Han K, Lee J, Kim M, Kim M . Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score-Matched Cohort Study. Diabetes Care. 2021; . DOI: 10.2337/dc20-3133. View

13.

Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H . Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017; 16(1):84. PMC: 5500953. DOI: 10.1186/s12933-017-0564-0. View

14.

Khan M, Hashim M, King J, Govender R, Mustafa H, Al Kaabi J . Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020; 10(1):107-111. PMC: 7310804. DOI: 10.2991/jegh.k.191028.001. View

15.

Wicke F, Glushan A, Schubert I, Koster I, Lubeck R, Hammer M . Performance of the adapted Diabetes Complications Severity Index translated to ICD-10. Am J Manag Care. 2019; 25(2):e45-e49. View

16.

Chang Y, Ho C, Chu C, Wang J, Jan R . Risk of retinal vein occlusion in patients with diabetes mellitus: A retrospective cohort study. Diabetes Res Clin Pract. 2020; 171:108607. DOI: 10.1016/j.diabres.2020.108607. View

17.

Feldman-Billard S, Dupas B . Eye disorders other than diabetic retinopathy in patients with diabetes. Diabetes Metab. 2021; 47(6):101279. DOI: 10.1016/j.diabet.2021.101279. View

18.

Alghadyan A . Retinal vein occlusion in Saudi Arabia: possible role of dehydration. Ann Ophthalmol. 1993; 25(10):394-8. View

19.

Hernan M, Robins J . Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016; 183(8):758-64. PMC: 4832051. DOI: 10.1093/aje/kwv254. View

20.

Chang H, Weiner J, Richards T, Bleich S, Segal J . Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012; 18(11):721-6. View